Search

Your search keyword '"Kairemo, Kalevi"' showing total 564 results
Start Over Author "Kairemo, Kalevi"
Sorry, I don't understand your search. ×
564 results on '"Kairemo, Kalevi"'

5. 18F-Fluoride: Benign Bone Disease

Author

Kairemo, Kalevi, Macapinlac, Homer A., Bomanji, Jamshed B., Series Editor, Gnanasegaran, Gopinath, Series Editor, Fanti, Stefano, Series Editor, Macapinlac, Homer A., Series Editor, and Kairemo, Kalevi, editor

Published
2020
Full Text
View/download PDF

7. 18F-Fluoride Imaging: Monitoring Therapy

Author

Etchebehere, Elba, Kairemo, Kalevi, Bomanji, Jamshed B., Series Editor, Gnanasegaran, Gopinath, Series Editor, Fanti, Stefano, Series Editor, Macapinlac, Homer A., Series Editor, and Kairemo, Kalevi, editor

Published
2020
Full Text
View/download PDF

8. Dynamic 18F-Fluoride Imaging

Author

Macapinlac, Homer A., Kairemo, Kalevi, Bomanji, Jamshed B., Series Editor, Gnanasegaran, Gopinath, Series Editor, Fanti, Stefano, Series Editor, Macapinlac, Homer A., Series Editor, and Kairemo, Kalevi, editor

Published
2020
Full Text
View/download PDF

9. Sodium Fluoride Imaging in Oncology

Author

Kairemo, Kalevi, Macapinlac, Homer A., Bomanji, Jamshed B., Series Editor, Gnanasegaran, Gopinath, Series Editor, Fanti, Stefano, Series Editor, Macapinlac, Homer A., Series Editor, and Kairemo, Kalevi, editor

Published
2020
Full Text
View/download PDF

12. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Author

Ahmadzadehfar, Hojjat, Matern, Ralf, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Svirydenka, Hanna, Sathekge, Mike, Kabasakal, Levent, Yordanova, Anna, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene, and Rahbar, Kambiz

Published
2021
Full Text
View/download PDF

15. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Author

Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, and Virgolini, Irene

Published
2021
Full Text
View/download PDF

17. Predictive Value of Quantitative Parameters of 18 F-FDG PET/CT in Patients with Liposarcoma.

Author

Martiniova, Lucia, Kamel, Serageldin, Kairemo, Kalevi, Benjamin, Robert, Somaiah, Neeta, Ravizzini, Gregory, and Haddad, Elise F. Nassif

Subjects
POSITRON emission tomography, COMPUTED tomography, LIPOSARCOMA, TREATMENT effectiveness, TOMOGRAPHY
Abstract

The purpose of this study was to evaluate the predictive features of baseline F-18-fluorodeoxy-D-glucose positron emission tomography (18F-FDG PET)/computed tomography (CT) parameters in patients with dedifferentiated liposarcomas (DDLPSs) and well-differentiated liposarcomas (WDLPSs) receiving systemic treatment. A total of 24 patients with liposarcoma who underwent longitudinal 18F-FDG PET/CT in systemic therapy were included. All volumetric segmentation of each tumor section and semiquantitative imaging parameters were extracted from the axial field of view from both PET and CT images. Maximum, mean, and minimum standardized uptake values (SUVmax, SUVmean, and SUVmin), Hounsfield units (HUs), and their respective changes from baseline and posttreatment were calculated. The voxel values from unenhanced CT images were correlated with PET-derived parameters. The 18F-FDG uptake decreased by more than 56% on average in responders for both SUVmax and SUVmean in DDLPS. There was a decrease in HUmax in DDLPS among responders. Using AUC > 0.8 as a reasonable predictor, we found that the ratios of SUVmaxD/HUmean, SUVmaxD/HUmedian, and SUVmeanD/HUmedian at baseline were significant indicators of the response to treatment in patients with liposarcoma. The changes in SUVmean and not just SUVmax parameters could be considered as accurate tumor response indicators. For the first time, we introduced baseline SUV/HU ratios as a valuable diagnostic tool in predicting liposarcoma treatment outcomes. This ability was not revealed by classic semiquantitative PET or CT parameters at baseline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis.

Author

Kairemo, Kalevi, Macapinlac, Homer A., Gouda, Mohammed, and Subbiah, Vivek

Subjects
*POSITRON emission tomography, *COMPUTED tomography, *GENE fusion, *PROTEIN-tyrosine kinases, *CANCER genes, *MEDULLARY thyroid carcinoma
Abstract

Selective RET inhibitors, such as selpercatinib and pralsetinib, have revolutionized the treatment of cancers with RET gene alterations. These inhibitors have shown remarkable clinical efficacy, particularly in RET-driven lung cancer, medullary thyroid cancer, and other solid tumors driven by RET gene fusions. The assessment of treatment response in oncology has been greatly enhanced by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), a valuable tool that measures tumor metabolism and provides early indicators of treatment effectiveness. This work explores the effectiveness of selective RET inhibitors in targeting RET-positive cancers and investigates the utility of FDG-PET in assessing treatment response. The paper includes insightful case studies that highlight the successful application of RET inhibitors in the treatment of RET-positive cancers. The findings suggest that FDG-PET has the potential to serve as a non-invasive biomarker for monitoring treatment response in patients with RET-positive cancers. However, further research is required to establish standardized criteria for interpreting FDG-PET scans in the context of selective RET inhibitors and to uncover the broader applications of FDG-PET in precision oncology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors.

Author

Kairemo, Kalevi, Gouda, Mohamed, Chuang, Hubert H., Macapinlac, Homer A., and Subbiah, Vivek

Subjects
*PROTEIN-tyrosine kinase inhibitors, *C-kit protein, *POSITRON emission tomography
Abstract

Background/Objectives: The inhibitory effects of tyrosine kinase inhibitors (TKIs) on glucose uptake through their binding to human glucose transporter-1 (GLUT-1) have been well documented. Thus, our research aimed to explore the potential impact of various TKIs of GLUT-1 on the standard [18F]FDG-PET monitoring of tumor response in patients. Methods: To achieve this, we conducted an analysis on three patients who were undergoing treatment with different TKIs and harbored actionable alterations. Alongside the assessment of FDG data (including SUVmax, total lesion glycolysis (TLG), and metabolic tumor volume (MTV)), we also examined the changes in tumor sizes through follow-up [18F]FDG-PET/CT imaging. Notably, our patients harbored alterations in BRAFV600, RET, and c-KIT and exhibited positive responses to the targeted treatment. Results: Our analysis revealed that FDG data derived from SUVmax, TLG, and MTV offered quantifiable outcomes that were consistent with the measurements of tumor size. Conclusions: These findings lend support to the notion that the inhibition of GLUT-1, as a consequence of treatment efficacy, could be indirectly gauged through [18F] FDG-PET/CT imaging in cancer patients undergoing TKI therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review.

Author

von Eyben, Finn Edler, Kairemo, Kalevi, and Kapp, Daniel S.

Subjects
PROSTATE-specific antigen, BIOMARKERS, PROSTATE cancer, PROSTATE cancer patients, RADICAL prostatectomy
Abstract

Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa. The SR was registered as InPLASY2023110084. We searched for studies on Google Scholar, PUBMED and reference lists of reviews and studies. We only included studies on uPSAs published in English and excluded studies of women, animals, sarcoidosis and reviews. Of the 115 included studies, 39 reported PSA assay methods and 76 reported clinical findings. Of 67,479 patients, 14,965 developed PSA recurrence (PSAR) and 2663 died. Extremely low PSA nadir and early developments of PSA separated PSAR-prone from non-PSAR-prone patients (cumulative p value 3.7 × 1012). RP patients with the lowest post-surgery PSA nadir and patients who had the lowest PSA at SRT had the fewest deaths. In conclusion, PSA for patients with localized PCa in the pre-PSAR phase of PCa is strongly associated with later PSAR and survival. A rising but still exceedingly low PSA at SRT predicts a good 5-year overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Utility of a simplified [18F] sodium fluoride PET imaging method to quantify bone metabolic flux for a wide range of clinical applications

Author

Puri, Tanuj, primary, Frost, Michelle L., additional, Moore, Amelia E. B., additional, Choudhury, Ananya, additional, Vinjamuri, Sobhan, additional, Mahajan, Abhishek, additional, Fynbo, Claire, additional, Vrist, Marie, additional, Theil, Jørn, additional, Kairemo, Kalevi, additional, Wong, James, additional, Zaidi, Habib, additional, Revheim, Mona-Elisabeth, additional, Werner, Thomas J., additional, Alavi, Abass, additional, Cook, Gary J. R., additional, and Blake, Glen M., additional

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial

Author

Subbiah, Vivek, primary, Anderson, Pete M., primary, Kairemo, Kalevi, primary, Hess, Kenneth, primary, Huh, Winston W., primary, Ravi, Vinod, primary, Daw, Najat C., primary, Somaiah, Neeta, primary, Ludwig, Joseph A., primary, Benjamin, Robert S., primary, Chawla, Sant, primary, Hong, David S., primary, Meric-Bernstam, Funda, primary, Ravizzini, Gregory, primary, Kleinerman, Eugenie, primary, Macapinlac, Homer, primary, and Rohren, Eric, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Kanerva, Anna, primary, Nokisalmi, Petri, primary, Diaconu, Iulia, primary, Koski, Anniina, primary, Cerullo, Vincenzo, primary, Liikanen, Ilkka, primary, Tähtinen, Siri, primary, Oksanen, Minna, primary, Heiskanen, Raita, primary, Pesonen, Saila, primary, Joensuu, Timo, primary, Alanko, Tuomo, primary, Partanen, Kaarina, primary, Laasonen, Leena, primary, Kairemo, Kalevi, primary, Pesonen, Sari, primary, Kangasniemi, Lotta, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

50. Data from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Pesonen, Sari, primary, Diaconu, Iulia, primary, Kangasniemi, Lotta, primary, Ranki, Tuuli, primary, Kanerva, Anna, primary, Pesonen, Saila K., primary, Gerdemann, Ulrike, primary, Leen, Ann M., primary, Kairemo, Kalevi, primary, Oksanen, Minna, primary, Haavisto, Elina, primary, Holm, Sirkka-Liisa, primary, Karioja-Kallio, Aila, primary, Kauppinen, Satu, primary, Partanen, Kaarina P. L., primary, Laasonen, Leena, primary, Joensuu, Tima, primary, Alanko, Tuomo, primary, Cerullo, Vincenzo, primary, and Hemminki, Akseli, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results